Abstract: An ultrasonic generator (10) includes an ultrasonic wave generation source (11), an ultrasonic wave converging portion (12), and a waveguide (13). The waveguide (13) includes a first shaft portion (21), a second shaft portion (22), and a jutting out portion (30). The first shaft portion (21) extends from the ultrasonic wave converging portion (12) to one side in a predetermined direction. The second shaft portion (22) is disposed on the one side in the predetermined direction relative to the first shaft portion (21) and extends in the predetermined direction. The jutting out portion (30) is provided between the first shaft portion (21) and the second shaft portion (22) in the predetermined direction. The jutting out portion (30) juts out more outward than the outer circumferential surfaces of the first shaft portion (21) and the second shaft portion (22) in a plane direction orthogonal to the predetermined direction.

Abstract: [Problem] To provide an additional use of a polysaccharide derivative such as a tissue adhesive material [Solution] According to some embodiments, a tissue adhesive material is provided, which is intended to be used for a hard and thick tissue and/or a connective tissue and comprises a polysaccharide derivative having such a structure that a group represented by formula (A) is introduced in an acidic, basic or amphoteric polysaccharide.

Abstract: To accurately perform movement control of a moving body, a machine tool includes a feed driver that moves a moving body in the machine tool, a feedback controller that feedback-controls the feed driver in accordance with a state variable, a friction compensator that, to compensate for rolling friction that occurs in the feed driver, adds, in advance, a friction compensation value obtained from measurement data of rolling friction or a friction compensation value calculated using a rolling friction model to a command value to be input to the feed driver, and a reverse response reducer that reduces, using the state variable of the feedback controller, a reverse response that occurs due to addition of the friction compensation value.

Abstract: [Object] To suppress a decrease in the adsorption performance of an adsorbent containing diatomaceous earth and a basic compound. [Solution] An adsorbent for adsorbing an acid gas contains diatomaceous earth, a basic compound, and a saccharide.

Abstract: An object of the present invention is to provide a novel agent for treating, preventing or improving an inflammatory disease or an allergic disease. The present invention provides an agent for treating, preventing or improving an allergic disease, or as an agent for treating, preventing or improving an inflammatory disease or an allergic disease, comprising, as an active ingredient, (±) 5,6-dihydroxy-8Z,11Z,14Z,17Z-eicosatetraenoic acid (5,6-DiHETE). The inflammatory disease can be an inflammatory disease due to an increase of calcium concentration in vascular endothelial cells, and the inflammatory disease can be an inflammatory disease developed in a tissue or organ selected from the group consisting of digestive organs, circulatory organs, respiratory organs, urinary organs, genital organs, brain, skin, eyes, and fat.

Abstract: The purpose of the present invention is to provide a set of two polypeptides for use in light-dependent genetic recombination in which the N-terminal side fragment and the C-terminal side fragment of a Cre protein having an amino acid sequence of SEQ ID NO: 1 respectively bind to two proteins light-dependently forming a dimer.

Abstract: Provided are a catalyst, which enables the production of a high molecular weight olefin polymer having a polar group and being usable for various applications at a high catalytic activity, and a method for producing such an olefin polymer. Use is made of, as a polymerization catalyst for an olefin having a polar group, a metal complex represented by general formula (C1) [wherein: M represents an element in group 10 of the periodic table; X represents a phosphorus atom (P) or arsenic atom (As); R5 to R11 are as described in claims; at least one of R6 and R7 is an aralkyl group represented by general formula (2) (wherein R12 to R21 are as described in claims); L represents an electron-donating ligand; and q is 0, ½, 1 or 2].

Abstract: The present invention provides D39-derived mutant PspA that does not undergo deamination and maintains stability as a molecule even around neutral pH range. Specifically, the present invention relates to a protein of the following (a) or (b): (a) a protein comprising the amino acid sequence as set forth in SEQ ID NO: 2 and having pneumococcal vaccine antigenic activity, and a protein substantially identical to the protein; or (b) a protein being a part of the amino acid sequence as set forth in SEQ ID NO: 2, wherein aspartic acid at position 254 is comprised in the part, and having pneumococcal vaccine antigenic activity, and a protein substantially identical to the protein.

Abstract: The present invention provides a comprehensive assay capable of comprehensively measuring interactive factors for a variety of different types of proteins. In the present invention, provided is a system for detecting activation of a protein by integrating, with mediation of a plurality of factors, changes in the transcriptional regulatory region of a gene whose expression is changed by activation of the protein. The stimulation response ratio of transcription activity before and after stimulation by ligands possessed by individual transcriptional regulatory regions is synergistically integrated, so that a highly sensitive reporter assay system can be constructed.

Abstract: A people flow control evaluation apparatus (100) evaluates an effect of people flow control. A position obtaining unit (110) extracts a position of a target person chronologically from people flow information (20) and stores the position of the target person as chronological position information (41). A direction calculation unit (120) calculates a movement direction of the target person chronologically based on the chronological position information (41) and stores the movement direction of the target person as a chronological movement direction (42). An effect evaluation unit (130) calculates an angular difference between the movement direction of the target person and a direction towards a destination position from the position of the target person chronologically, and evaluates the effect of the people flow control using a chronological change of the angular difference calculated chronologically.

Abstract: An imaging flow cytometer includes: a flow channel in which an observation object flows and a length in a width direction is longer than a length in a height direction; an acoustic element configured to apply acoustic waves as standing waves to the flow channel; a light source that irradiates the flow channel with illumination light; an image sensor configured to image at least a line included in a cross section of the observation object crossing a flow line direction which is a direction in which the observation object flows in the flow channel by measuring or imaging the observation object passing through a position irradiated with the illumination light; and circuitry configured to generate an image in which the observation object is scanned in the flow line direction on the basis of a plurality of captured images acquired by the imaging unit imaging the line in a time series.

Abstract: A method for isolating and concentrating an extracellular vesicle group derived from a cancer cell involves contacting a substance which has affinity towards a carbohydrate antigen CA19-9 with an extracellular vesicle group which has been isolated from blood derived from a patient, and isolating and concentrating an extracellular vesicle group.

Abstract: The present invention relates to a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: wherein in Formula (I), definitions of R1, R2, L, m, and n are each shown in the specification.

Abstract: A polarization splitting device includes a substrate, and a polarization splitting layer having a structure element pattern including a plurality of structure elements each having two-fold rotational symmetry, and formed on an upper surface of the substrate. The polarization splitting layer splits first to sixth polarization components included in object light, and focuses respectively at first to sixth focal positions on a focal plane. The structure element pattern includes a first structure element pattern for focusing the first and second polarization components, a second structure element pattern for focusing the third and fourth polarization components, and a third structure element pattern for focusing the fifth and sixth polarization components, and a pattern constituted by a first structure element, a second structure element, and a third structure element is set as a unit pattern, and a plurality of unit patterns are two-dimensionally arranged.

Abstract: It is an object of the present invention to develop a virus preparation comprising an oncolytic HSV having, in vivo, more effective cancer cell-killing activity than the antitumor effects of existing oncolytic HSVs. Specifically, the present invention relates to a virus preparation for the treatment of a cancer, comprising an HSV (herpes simplex virus) having a receptor-retargeted gD mutation and at least one membrane fusion activity-promoting region on the genome, and a method for treating cancer using the aforementioned virus preparation.

Abstract: An air conditioning system (1) includes a carbon dioxide separation device (20) configured to separate some or all of carbon dioxide from air that contains carbon dioxide, an electrolytic reduction device (30) configured to generate a hydrocarbon and oxygen using the separated carbon dioxide as a raw material, and an oxygen supply amount control device (40) configured to supply some or all of the oxygen generated by the electrolytic reduction device (30) to a space to be processed (10).

Abstract: Provided are a catalyst and a method that enable the production of an olefin-based polymer, which has a polar group and is usable for various applications, at high catalytic activity. A metal complex shown in general formula (C1) (in the formula, M represents a palladium atom or a nickel atom, X represents a phosphorus atom (P), R5-R9 are as set forth in the claims, L represents an electron donating ligand, and q is 0, ½, 1, or 2) is used as a catalyst for polymerization of an olefin having a polar group.

Abstract: [Problem] Provided is an oxyethylene chain-containing polymer having excellent biocompatibility and still having excellent reactivity. [Solution] An oxyethylene chain-containing polymer according to the present invention is represented by the following general formula (1): (wherein, in the general formula (1), R1 is —(CH2)p—SH, —(CH2)p—N3, (CH2)p—NH2, or —(CH2)p—COOH, and p is an integer of 1 to 5; R2 to R4 are each independently hydrogen or a C1-10 alkyl group; R5 is a C1-10 alkyl group; R6 is hydrogen or a C1-5 alkyl group; R7 is a C1-10 alkyl group; n is an integer of 5 to 1000; m is an integer of 1 to 10; and q is an integer of 0 to 5).

Abstract: A mammalian or avian cell line that expresses high levels of human influenza virus receptors is provided. In one embodiment, the cell line supports human influenza virus, e.g., human A/H3 influenza virus, isolation and growth much more effectively than corresponding conventional (unmodified) cells or in corresponding human virus receptor-overexpressing cells, and the propagated viruses may maintain higher genetic stability than in the corresponding cells.

Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.